Epidemiology and Clinical Outcomes in Children with Malignant Lymphoma in Korea: Retrospective Study.
- Author:
Chuhl Joo LYU
1
;
Im Joo KANG
;
Hong Hoe KOO
;
Hoon KOOK
;
Soon Ki KIM
;
Thad T GHIM
;
Hack Ki KIM
;
Hwang Min KIM
;
Heung Sik KIM
;
Hyung Nam MOON
;
Kyung Duk PARK
;
Kyung Bae PARK
;
Byung Kiu PARK
;
Sang Gyu PARK
;
Young Sil PARK
;
Jae Sun PARK
;
Joon Eun PARK
;
Hyeon Jin PARK
;
Jong Jin SEO
;
Ki Woong SUNG
;
Hee Young SHIN
;
Hyo Seop AHN
;
Chang Hyun YANG
;
Keon Hee YOO
;
Kyung Ha RYU
;
Eun Sun YOO
;
Kun Soo LEE
;
Kwang Chul LEE
;
Soon Yong LEE
;
Young Ho LEE
;
Young Tak LIM
;
Pil Sang JANG
;
Nak Gyun CHUNG
;
Dae Chul JEONG
;
Hye Lim JUNG
;
Bin CHO
;
Yong Mook CHOI
;
Jeong Ok HAH
;
Jung Woo HAN
;
Tai Ju HWANG
Author Information
1. The Korean Society of Pediatric Hematology-Oncology, Korea. hsahn@snu.ac.kr
- Publication Type:Review
- Keywords:
Malignant lymphoma;
Hodgkin's disease;
Non-Hodgkin lymphoma;
Epidemiology;
Incidence
- MeSH:
Burkitt Lymphoma;
Child*;
Clinical Protocols;
Diagnosis;
Drug Therapy;
Drug Therapy, Combination;
Epidemiologic Studies;
Epidemiology*;
Female;
Hematopoietic Stem Cell Transplantation;
Hodgkin Disease;
Humans;
Incidence;
Korea*;
Lymphatic Diseases;
Lymphoma*;
Lymphoma, Non-Hodgkin;
Male;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Surveys and Questionnaires;
Radiotherapy;
Retrospective Studies*;
Survival Rate
- From:Korean Journal of Pediatric Hematology-Oncology
2004;11(2):153-163
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Malignant lymphoma is the primary malignant tumor derived from lymphoid organs. It is composed of Hodgkin's disease and non-Hodgkin lymphoma. Recently, survival rate is on the rise due to improved combination chemotherapy, radiotherapy and high dose chemotherapy followed by hematopoietic stem cell transplantation. In South Korea, no epidemiologic studies concerning malignant lymphoma in the pediatric age group has been performed. Therefore, the Korean Society of Pediatric Hematology-Oncology retrospectively analyzed the incidence, pathologic subtypes, treatment strategies, and survival rates of pediatric malignant lymphomas in South Korea. METHOD: Questionnaires were made and sent to a group of training hospitals, with a return of 580 questionnaires from 24 hospitals. Among them, 517 reports were suitable for analysis. RESULTS: Among the 517 cases, Hodgkin's disease accounted for 58 cases and non-Hodgkin's lymphoma for 459 cases. Male to female ratio for malignant lymphoma was 2.7. Mean age at diagnosis was 8.3 years. Among the pathologic subtypes, mixed cellularity was the most frequent subtype for Hodgkin's disease. Most (70.7%) cases of non-Hodgkins lymphoma belonged to high grade NHL. Burkitt lymphoma accounted for 102 cases, and lymphoblastic lymphoma was found in 58 cases. Peripheral lymphadenopathy was the most common presenting sign upon diagnosis. B symptoms were significantly more frequent in Hodgkin's disease patients than in non-Hodgkin lymphoma patients. The Complete response rate was 62.1% for non-Hodgkin's lymphoma, and 82.8% for Hodgkin's disease. Overall 5 year survival rate was 60.0% in non-hodgkin's lymphoma, and 84.8% in Hodgkin's disease. CONCLUSION: The annual incidence of malignant lymphoma in Korea is 4.7 per million. In cases of chemotherapy-sensitive, refractory or relapsed malinant lymphoma, high dose chemotherapy followed by hematopoietic stem cell transplantation is vital for improved survival. For more systematic analysis of epidemiology on malignant lymphomas, better surveillance mechanisms on the occurrence of malignant lymphomas are crucial, and establishment of standardized treatment protocol for malignant lymphoma is required.
